Compare JRSH & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JRSH | BTAI |
|---|---|---|
| Founded | 2016 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Apparel | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.1M | 35.6M |
| IPO Year | 2017 | 2018 |
| Metric | JRSH | BTAI |
|---|---|---|
| Price | $3.20 | $1.66 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $4.00 | ★ $26.67 |
| AVG Volume (30 Days) | 70.3K | ★ 285.4K |
| Earning Date | 05-25-2026 | 01-01-0001 |
| Dividend Yield | ★ 6.27% | N/A |
| EPS Growth | ★ 56.25 | N/A |
| EPS | ★ 0.15 | N/A |
| Revenue | ★ $145,812,006.00 | N/A |
| Revenue This Year | $11.64 | N/A |
| Revenue Next Year | $10.06 | $261.81 |
| P/E Ratio | $21.33 | ★ N/A |
| Revenue Growth | ★ 24.43 | N/A |
| 52 Week Low | $2.81 | $1.17 |
| 52 Week High | $3.70 | $8.08 |
| Indicator | JRSH | BTAI |
|---|---|---|
| Relative Strength Index (RSI) | 48.32 | 50.49 |
| Support Level | $3.03 | $1.50 |
| Resistance Level | $3.52 | $1.72 |
| Average True Range (ATR) | 0.10 | 0.10 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 18.77 | 50.94 |
Jerash Holdings (US) Inc along with its subsidiaries, is a manufacturer and exporter of customized, ready-made sport and outerwear from knitted fabric from its production facilities in Jordan. The company manufactures for retailers, including Walmart, Costco, Sears, Hanes, Columbia, Land's End, VF Corporation, and Philip-Van Heusen, which owns brands such as The North Face, Nautica, Timberland, Wrangler, Lee, Jansport, Calvin Klein, Tommy Hilfiger, IZOD, and Speedo. It derives its revenue from the manufacturing and sales of outerwear in the United States. The company's product offering consists of jackets, polo shirts, crew neck shirts, pants, and shorts made from knitted fabric. Geographically, the company generates maximum revenue from the United States.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.